<DOC>
	<DOCNO>NCT00656084</DOCNO>
	<brief_summary>To determine efficacy ( response rate ) produce combination Gemzar , Novantrone , Rituxan relapse refractory MCL</brief_summary>
	<brief_title>Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Stage III IV , histologically confirm relapsed refractory MCL review SI Is CD20 positive ( immunohistochemistry FACS ) Is Cyclin D positive ( immunohistochemistry FACS ) Has receive prior chemotherapy ( require minimum 1 prior therapy ) Has receive prior treatment Rituxan Has ECOG Performance Status ( PS ) 02 Is great equal 18 year age Has appropriate laboratory value ( please refer protocol specific laboratory value ) If history cardiac disease indicate , patient LVEF great equal 50 % ( MUGA ) Has negative serum pregnancy test within 7 day prior registration ( female patient childbearing potential ) If fertile , patient ( male female ) agree use acceptable method birth control avoid pregnancy duration study period 2 month thereafter Has sign Patient Informed Consent Form Has sign Patient Authorization Form Has lymphomas classify MCL Has prior treatment Gemzar and/or Novantrone A history know hypersensitivity Gemzar , Novantrone , Rituxan , component drug Has history hypersensitivity murinecell derive therapeutic Has LVEF indicative cardiac condition ( LVEF &lt; 50 % ) Is receive concurrent immunotherapy Has evidence CNS involvement Has serious uncontrolled intercurrent medical psychiatric illness , include serious infection Has history malignancy within last 5 year ( except cure basal cell carcinoma skin carcinoma insitu uterine cervix ) , could affect diagnosis assessment study drug Is pregnant nurse woman Is unable comply requirement study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>